Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — FY2018 Earnings Presentation
20 slides from Lincoln Pharmaceuticals's earnings presentation, 2018
Slide 1: Q4 and Full Year FY2018 Earnings Presentation
Q4 and Full Year FY2018 Earnings Presentation Providing Affordable and Innovative medicines for healthier lives
Slide 2: Highlights
Highlights FY2018 vs. FY2017 Management Perspective “Continuing on strong growth momentum we gained during last few o Total Income of Rs. 3,670.9 million quarters, we are pleased to report stellar performance with 23% o EBITDA of Rs. 577.7 million, up 16.7% growth in the net profit during the year F
Slide 3: Performance Overview
Performance Overview Consolidated Financial Performance Q4 y-o-y Q3 q-o-q Full Year y-o-y Particulars FY2018 FY2017 Growth (%) FY2018 Growth (%) FY2018 FY2017 Growth (%) Total Income 679.8 1,208.7 (43.8)% 830.2 (18.1)% 3,670.9 3,680.7 (0.3)% EBITDA 105.1 39.9 163.2% 189.8 (44.7)% 577.8 495.1 16.7% M
Slide 4: Annual Revenue Breakup: Therapeutic Area and Geography
Performance Overview Annual Revenue Breakup 4% 2% 3% 2% General Anti Infectives 5.7% 24% 9% 1.1% 17.6% 2.1% Respiratory Systems 2.2% Therapeutic Area 25.1% 14% 25.5% Alimentary Tract and Metabolism 0.4% 10.3% Genito Urinary System and Sex Hormones 2.7% 1.5% 13% 15% Musculo-Skeletal System FY2018 14%
Slide 5: Quarterly Revenue Breakup: Therapeutic Area and Geography
Performance Overview Quarterly Revenue Breakup 4% 2% 3% 2% General Anti Infectives 9% 24% 15.1% Respiratory Systems Therapeutic Area 23.6% 24.8% 14% 0.2% Alimentary Tract and Metabolism 28.8% 1.7% 1.1% Genito Urinary System and Sex Hormones 13% 15% Musculo-Skeletal System 2.6% Q4 FY2018 14% Q4 FY201
Slide 6: Performance Trend
Performance Trend Total Income (Rs. million) and Y-o-Y Growth (%) Q4 FY2018 Highlights (Y-o-Y) 64.4% 18.1% (5.9)% 10.3% o Net profit during the quarter increased more (43.8)% than 400% YoY. Profitability improved on the 1,208.7 1,524.0 926.5 830.2 679.7 account of: Q4 FY17 Q1 FY18 Q2 FY18 Q3 FY18 Q4
Slide 7: Performance Trend
Performance Trend Net Debt / LTM EBITDA Total Debt / Net Worth 2.0x 0.6x 1.9x 0.5x 1.2x 0.3x 1.0x 0.9x 0.2x 0.2x Q4 FY17 Q1 FY18 Q2 FY18 Q3 FY18 Q4 FY18 Q4 FY17 Q1 FY18 Q2 FY18 Q3 FY18 Q4 FY18 ROCE1 RONW2 16.7% 14.9% 15.4% 14.4% 14.5% 14.5% 13.7% 13.0% 11.0% 11.3% Q4 FY17 Q1 FY18 Q2 FY18 Q3 FY18 Q4
Slide 8: Leverage Profile
Leverage Profile (Rs. million) Mar 31st, 2018 Mar 31st, 2017 Long Term Debt 177.6 217.7 Credit Rating Short Term Debt 1,049.4 908.9 o The Company’s debt facilities have been assigned Total Debt 1,226.9 1,126.6 the following ratings by ICRA Long term bank facilities: A- Less: Cash & Cash Equivalent
Slide 9: Recent Developments
Recent Developments 1 Developed new NDDS formulation Ondansetron Oral Spray (Domi Up) for the first time in India • Currently the Ondansetron formulation is available in the form of tablet, syrup and injectable. Lincoln Pharma has developed Ondansetron (Domi Up) as an oral spray which is first in In
Slide 10: Research & Development
Research & Development Research Facilities R&D Expenditure (Rs. mn) and as % of Sales 3.2% 2.4% 2.0% 2.7% 117.3 Senior Scientist 15 1.6% 88.5 Junior Scientist 18 72.6 79.5 Analysts 18 Regulatory Personnel 12 34.3 Administrative Personnel 9 Others 6 Total 78 FY14 FY15 FY16 FY17 FY18 10
Slide 11: A Leading Pharmaceutical Company
A Leading Pharmaceutical Company Research & Development Department Market Presence Presence in Presence in 4 Patents Granted 1,000 Registered Dossiers 60+ 25 25 Patents Applications 550 Ongoing Applications Countries States across India 300+ 43rd 15+ Formulations Developed Rank in AIOCD Therapeutic
Slide 12: Key Milestones
Key Milestones Received WHO – Becomes Public Covered 80% of all Developed & Launched Robust business growth in GMP for plant / Limited Company India Market 3 NDDS products domestic & international production unit from a Partnership markets 2016-17 2017-18 2015-16 2014-15 2010-11 2001 2000 1997-98 19
Slide 13: Global Footprint
Global Footprint Presence over 60 countries in Europe, Latin America, Africa, Asia Pacific and South East Asia; 22 states across India Jammu Uttaranchal Chandigarh Delhi Europe: Ambala Ghaziabad France Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad Kolkata Indore Raipur Nagpur Cuttack Vijayawada Che
Slide 14: Best-in-Class Facilities
Best-in-Class Facilities Certifications: WHO-GMP Certified; ISO9001:2008 Certified R&D Center: Approved by Government of India; Team of 30 scientists for R&D Green Energy: Windmill project for captive consumption Dosage Forms Produced at Unit 1 Dosage Forms Produced at Unit 2 Description Annual Capa
Slide 15: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Sterile Ophthalmic Dermatologist Gyneacologial Gastro Intestinal Anti Allergic / Anti- Eye Preparation Products Range asthmatics Drops/Ointment Anti-bacterial / Vitamins / Minerals Analgesic / Anti- Anti-diuretics/ Anti-malarial Anti-viral/ Anti-
Slide 16: Key Brands
Key Brands Domestic Market International Market Calcium Carbonate 1250 mg+ 11 Antioxidants + 33 Essential Micronutrients + Each squirts (spray) delivers 2 Vit. D3 250 I.U. Tablets 5 Amino Acids mg Ondansetron Hydrochloride α-β Arteether Injection Artesunate for Injection 60 mg Anti Cold Capsules 150
Slide 17: Key Recent Developments
Key Recent Developments o Progesterone spray • Unique delivery system for accurate 25mg delivery of micronized progesterone/Spray • Formulation dispensed in mist form which provides local as well as systemic effect of Progesterone via vaginal route covering large area of vaginal cavity • Better pati
Slide 18: Key Recent Developments
Key Recent Developments o Arteether injection 150 mg/ml • Unique low-viscosity sterile formulation for malaria • Less painful and low volume (1 ml) IM formulation • Convenient patient administration • Patented technology o Namcold DX • First time in India: ‘Extended Release’ Oral Suspension • The on
Slide 19: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfor
Slide 20: Corporate Office
CORPORATE OFFICE LINCOLN HOUSE B/h. Satyam Complex, Science City Road, Sola, Ahmedabad – 380 062. Gujarat, INDIA. Phone :+91-79-67778000 • Fax:+91-79-67778062 E-mail:info@lincolnpharma.com www.lincolnpharma.co.in KP Sompura, Finance Head sompurakp@lincolnpharma.com Lincoln Pharmaceuticals +91 79 677
Lincoln Pharmaceuticals — FY2018 Earnings Presentation on 6ix